

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Rhonan Ford et al. Art Unit : Unknown
Serial No. : 10/566,320 Examiner : Unknown
Filed : January 26, 2006 Conf. No. : 3505
Title : QUINOLINE DERIVATES AND THEIR USE IN THERAPY

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. Copies of International Search Reports for WO 2004/106305 and WO 2005/009968 are also enclosed.

Applicants provide a listing below of a commonly owned co-pending U.S. patent application that is included on the PTO-1449. Please note that the commonly owned co-pending U.S. patent application was filed as a U.S. national phase patent application under 35 U.S.C. §371, and therefore the listing includes a reference to the PCT publication number for the commonly owned co-pending U.S. patent application.

The PTO-1449 lists the commonly owned co-pending U.S. patent application by its corresponding published PCT publication number.

U.S. Patent Application Serial No./
Published U.S. Patent Application

10/558,898

Corresponding Published PCT
Patent Application

WO 2004/106305

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-490US1.

Respectfully submitted,

Date: December 18, 2006

Catherine M. McCarty Reg. No. 54,301

Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
21510877.doc

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-490US1	Application No. 10/566,320
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.	
		Filing Date January 26, 2006	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/N.C./	AA	US 2001-0003121	06/07/2001	Baxter et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/N.C./	AB	WO 03/080579	10/02/2003	WIPO				
/N.C./	AC	WO 2004/106305	12/09/2004	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/N.C./	AD	STN International, file CHEMCATS, Accession no. 2002:1977776, 9 July 2002, BAS 1098675, "Cyclopropanecarboxamide, N-(2-methyl-5-quinolinyl)-", CAS Registry No. 333432-34-1
/N.C./	AE	STN International, file CHEMCATS, Accession no. 11 January 2001, Cyclopropanecarboxamide, N-(2,6-dimethyl-5-quinolinyl)-(9CI)(CA INDEX NAME), CAS Registry No. 313479-89-9

Examiner Signature /Nizal Chandrakumar/	Date Considered 05/15/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	